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The authors’ recent discovery that glycogen synthase kinase-3β
(GSK-3β) participates in colon cancer cells’ survival and proliferation
prompted us to investigate whether GSK-3β inhibition alters pro-
liferation of colon cancer cells in vivo. Groups of four or five athymic
mice (Balb/c, nu/nu) with subcutaneous xenografts of SW480 human
colon cancer cells were treated with dimethyl sulfoxide (DMSO) or
different doses (1, 2 and 5 mg/kg body weight) of either small-
molecule GSK-3β inhibitor (SB-216763 and AR-A014418) by intraper-
itoneal injection three times per week for 5 weeks. Compared with
DMSO (a diluent of the GSK-3β inhibitors) as a control, either GSK-3β
inhibitor significantly inhibited proliferation of cancer cell xenografts
in the rodents in a dose-dependent manner. Histochemical and
immunohistochemical analysis of tumor xenografts demonstrated a
significant, dose-dependent decrease in fractions of proliferating
cells and an increase in the incidence of apoptosis of cancer cells in
mice treated with either GSK-3β inhibitor. No adverse events or effects
were observed in the rodents during the course of treatment, except
for rare lethal accidents due to intraperitoneal injection. Morphological
examination showed no apparent pathologic changes in major organs
including the lungs, liver, pancreas, kidneys, spleen and large bowel of
rodents treated with DMSO and the GSK-3β inhibitors. The results
indicate that the GSK-3β inhibitors would be a novel class of
therapeutic agent for colon cancer. (Cancer Sci 2007; 98: 1388–1393)
A striking contribution toward understanding the molecularbasis of cancer has been the identification of targets for
diagnosis and treatment of this disease. A target of great interest
among the molecules altered in cancer is a set of protein kinases,
most proto-oncogene products, that mediate complex cellular
signaling networks in physiological conditions and evoke oncogenic
signaling in cancer development.(1,2) Among the novel therapeutic
strategies that led to a variety of therapeutic agents under clinical
development, one approach utilizes humanized monoclonal
antibodies directed against the extracellular domains of trans-
membrane receptor-type protein kinases. Another approach is
the generation of small-molecule analogs of ATP targeting the
kinase domain. Many small-molecule inhibitors of these kinases
are being developed for target-directed therapies of cancer.(1–3)
GSK-3β, a molecular target of interest in this study, is a
multifunctional serine/threonine protein kinase that regulates
fundamental cellular pathways, depending on its substrates for
phosphorylation and its subcellular localization.(4–6) On the basis
of its primary pathologic activities in NIDDM,(7–9) and AD,(10,11)
GSK-3β has emerged as a promising target in relation to gener-
ating a novel strategy and developing new drugs for treatment of
adult-onset chronic and progressive diseases.(12–14) Because a
variety of transcription factors (e.g. c-Jun, c-Myc), cell cycle regu-
lators (e.g. cyclin D1) and proto-oncoproteins (e.g. β-catenin,
Gli2) are GSK-3β substrates for phosphorylation-dependent
protein degradation in the ubiquitin–proteasome system, GSK-
3β is recognized as a putative suppressor of cellular neoplastic
transformation and tumor development (reviewed in(15)). Another
line of study, however, indicates that GSK-3β plays a crucial
role in cell survival signaling under physiological conditions,
presumably by stimulating NF-κB-mediated gene transcription.(16,17)
These conflicting notions as to the biological properties of GSK-
3β in cells have promoted investigation of the pathologic roles
of the kinase in cancer, which are characterized by irreversible
deregulation in cell survival, proliferation and differentiation.(18)
Under normal conditions, GSK-3β is constitutively active in
cells, and its activity is regulated by the balance between the
levels of phosphorylation at its S9 and Y216 residues.(4–6)
Recently, the authors found that increased GSK-3β expression
and activity and deregulation of its activity by impairment in
differential phosphorylation in S9 and Y216 residues are chara-
cteristic of both colon cancer cell lines and clinical CRC, which
was unrelated to β-catenin activation in tumor cells. Functional
analysis by genetic depletion of expression and pharmacological
inhibition of activity of the kinase demonstrated the novel
pathologic roles of GSK-3β in promoting cancer cell survival
and proliferation and in interfering with those undergoing apop-
tosis in CRC, which contradicts its predicted role as a tumor
suppressor.(19) By developing and using the non-radioisotopic in
vitro kinase assay (NRIKA), the authors detected increased
activity of GSK-3β in colon, stomach, pancreas and liver cancer
cells in comparison with HEK293, where the kinase activity is
seemingly regulated by differential phosphorylation; similar
pathologic properties of GSK-3β were also observed in cancer
cells of these types.(20) On this basis, the authors warrant proposing
this kinase as a potential therapeutic target in gastrointestinal
cancer (PCT/JP2006/300160).
Similar observations in colon and pancreas cancer cells have
been reported,(21,22) in parallel with the authors’ earlier stud-
ies.(19,20) These studies raise an important concern, namely,
whether inhibition of GSK-3β activity by small-molecule
inhibitors alters proliferation of human colon cancer cells
xenografted into rodents. The present study was undertaken to
address this question. The pathological effects of GSK-3β inhi-
bition in the major organs of the rodents were also monitored.
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Materials and Methods
Rodents. Pathogen-free 6-week-old female athymic nude mice
(Balb/c, nu/nu) were supplied by Japan SLC (Hamamatsu, Japan).
After quarantine for 2–3 weeks in pathogen-free conditions at
the Animal Experiment Facility in the Advanced Science
Research Center of the University, these mice were subjected to
inoculation of colon cancer cells and subsequent treatment. All
experiments were conducted under strict controls according to
the Guidelines for the Care and Use of Laboratory Animals in
Kanazawa University and in accordance with the national
guidelines for animal usage in research in Japan.
Inoculation of cancer cells and treatment. Cells from the human
colon cancer cell line SW480 (American Type Culture Collection,
Manassas, VA, USA) were cultured in DMEM (Gibco, Grand
Island, NY, USA) supplemented with 10% FBS (Gibco). Cells
for inoculation were harvested from subconfluent cultures by
brief treatment with 0.25% trypsin and 0.02% EDTA (Gibco).
After inactivation of trypsin in the cells’ suspension by adding
fresh medium, the cells were resuspended in PBS and used for
subcutaneous inoculation of 1 × 106 cells in 200 µL PBS into
each of 35 mice. Two weeks after inoculation, subcutaneous tumors
that were formed and visible in all mice were size-matched (the
diameter of each tumor was approximately 2 mm), and the mice
were randomly assigned to seven groups (five mice each) for
treatment with DMSO (a diluent of the GSK-3β inhibitors) or
either of two small-molecule GSK-3β inhibitors, SB-216763
(Sigma-Aldrich, St Louis, MO, USA) and AR-A014418
(Calbiochem, San Diego, CA, USA).
All mice were given intraperitoneal injections of a 200-µL
aliquot of 75% DMSO or either GSK-3β inhibitor dissolved
in 200 µL of DMSO at different doses (1 mg/kg, 2 mg/kg or
5 mg/kg body weight), respectively, three times a week for 5 weeks
(Fig. 1). The doses of GSK-3β inhibitors corresponded to the
concentrations of the respective inhibitors in culture media used
in the treatment of cells in vitro in the authors’ earlier studies.(19,20)
Assuming that 60% of body weight is accounted for by body
fluid in each mouse, the doses of inhibitors of 1 mg/kg, 2 mg/kg
and 5 mg/kg (body weight) correspond approximately to
concentrations of 5 µM, 10 µM and 25 µM in culture media,
respectively. Throughout the experiment, all mice were carefully
observed for adverse events every day, and tumors were measured
in two dimensions every week. Tumor volume (cm3) was calcu-
lated using the formula: 0.5 × a2 × b, where a is the smallest
tumor diameter (cm) and b is the largest.(23)
Necropsy and histopathologic examination. Following treatment,
all mice were euthanized. At necropsy, tumor and the major
organs (lungs, liver, pancreas, spleen, kidney and large bowel) were
removed, fixed in 10% neutral-buffered formalin and embedded
in paraffin for histopathologic and immunohistochemical
examination. Paraffin sections of these organs and tumors were
stained with HE for histopathologic examination by a certified
pathologist (A.O.). Tumors removed from all rodents at
necropsy were weighted before fixation.
Histochemical and immunohistochemical analysis. Expression and
localization of GSK-3β, β-catenin and PCNA in tumor tissues
were immunohistochemically examined using the avidin–biotin–
peroxidase complex method as described in the authors’ previous
studies,(24,25) with certain modifications. Representative paraffin
sections placed on silanized slides (Dako, Glostrup, Denmark)
were treated by microwaving in citrate buffer to unmask antigens
and incubated with 0.3% H2O2 in methanol and then with 10%
normal goat serum to block non-specific immunohistochemical
reactions. The pretreated paraffin sections were incubated with
the rabbit monoclonal antibody to human GSK-3β (diluted
1:100; Epitomics, Burlingame, CA, USA), polyclonal antibody
to β-catenin (diluted 1:100; Cell Signaling Technology, Beverly,
MA, USA) or PCNA (diluted 1:100; Santa Cruz Biotechnology,
Santa Cruz, CA, USA). After incubation with either antibody, the
sections were incubated with the biotinylated goat anti-rabbit
IgG (Vector, Burlingame, CA, USA) diluted 1:200 in PBS containing
1% BSA and 10% normal mouse serum (DakoCytomation,
Glostrup, Denmark) to prevent cross-reactions with endogenous
mouse IgG.
Cancer cells undergoing apoptosis were histochemically
detected in the representative section of tumor tissues using the
TUNEL method,(26) with the in situ apoptosis detection TUNEL
kit (Takara, Kusatsu, Japan). The frequency of proliferating cells
and cells undergoing apoptosis in the tumors was calculated by
counting PCNA-positive cells and TUNEL-positive cells and
debris (apoptosis changes), respectively. In each tumor, a total
of more than 200 nuclei per high-power microscopic field was
counted and scored for PCNA-positive nuclei and apoptosis
changes, respectively. The mean scores for PCNA-positive
nuclei and apoptosis changes in five high-power fields were then
calculated with SD.
Statistical analysis. Body weight of mice, tumor volume, tumor
weight (at necropsy) and scores of PCNA-positive cells and
TUNEL-positive cells in each treatment group were expressed
as means ± SD. The statistical significance of differences among
the data was determined with the one-way anova followed by
Fisher’s PLSD post hoc test. Values of P < 0.05 were considered
significant.
Results
Representative rodents in the respective groups of mice treated
with DMSO or different doses of GSK-3β inhibitors are shown
in Fig. 2. In all mice treated with DMSO, SW480 colon cancer
cells formed subcutaneous tumors with a mean volume of
2.07 ± 0.17 cm3 After 5 weeks’ treatment with either GSK-3β
inhibitor, there was a significant and dose-dependent decrease in
tumor volume in mice treated with different doses (1 mg/kg,
2 mg/kg, and 5 mg/kg body weight) of inhibitor, in comparison
with those treated with DMSO. As shown in Fig. 3a, the effect
of GSK-3β inhibitors against tumor proliferation increased as
treatment duration grew longer. Following 3 weeks’ treatment
(i.e. as of week 5 in Fig. 3a), Fischer’s PLSD post hoc test showed
significant differences in tumor volume between mice treated
with DMSO and those treated with either inhibitor, and between
                  
 
Fig. 1. Design and protocol of the animal experiment. At week 0,
1 × 106 SW480 human colon cancer cells were subcutaneously
inoculated into each mouse. Two weeks later subcutaneous tumors
that were formed in all mice were size-matched and the mice were
randomly assigned to seven groups for treatment with dimethyl
sulfoxide (DMSO, a diluent of the GSK3β inhibitors) or either of two
small-molecule GSK-3β inhibitors, SB-216763 and AR-A014418. DMSO
and indicated doses of the GSK-3β inhibitors were given to mice by
intraperitoneal injections three times per week. After 5 weeks’
treatment, all mice were euthanized for necropsy. At the beginning of
treatment, one mouse in each of the groups treated with the GSK-3β
inhibitors died because of a lethal accident (i.e. bleeding in the
peritoneal cavity) due to the intraperitoneal injection.
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mice treated with 1 mg/kg of inhibitors and those treated with
2 mg/kg or 5 mg/kg of them. Statistically similar differences
were found in tumor weights at necropsy between mice with
the respective treatments (Fig. 3b). There were no statistically
significant differences in tumor volume or weight between mice
treated with any doses of SB-216763 and AR-A014418, or
between those treated with 2 mg/kg and 5 mg/kg of inhibitor,
respectively.
Histological examination of the tumors showed medullary
proliferation of oval and polyhedral cancer cells in all cases
(upper panels in Fig. 4a,b and Fig. 5). Little prominent host
reaction, such as inflammation and fibrosis, was associated with
the tumors. The effects of the GSK-3β inhibitors on tumor cells’
survival and proliferation were investigated using histochemical
(TUNEL) and immunohistochemical (PCNA) staining of the
Fig. 4. Scores of terminal deoxynucleotidyl transferase–mediated
dUTP nick-end labeling (TUNEL)- and proliferating cell nuclear antigen
(PCNA)-positive cells, respectively, in tumor tissues removed from mice
at necropsy after 5 weeks’ treatment with dimethyl sulfoxide (DMSO)
and indicated doses (1 mg/kg, 2 mg/kg, and 5 mg/kg body weight) of
GSK-3β inhibitors. Representative sections of histochemical (TUNEL) and
immunohistochemical (PCNA) staining are shown in the upper panels.
There were (a) dose-dependent increases in TUNEL-positive cell rates
and (b) decreases in PCNA-positive cell rates in tumors treated with SB-
216763 or AR-A014418 (P < 0.05), compared with those treated with
DMSO.
Fig. 2. Representative rodents in groups of mice treated with dimethyl
sulfoxide (DMSO) or indicated doses of GSK-3β inhibitors, SB-216763
and AR-A014418. After 5 weeks’ treatment with either inhibitor, there
was significant dose-dependent decrease in tumor size in mice treated
with different doses (1 mg/kg, 2 mg/kg, and 5 mg/kg body weight,
shown at the top of the panels) of the inhibitors, in comparison with
those treated with DMSO. Arrows point to subcutaneous tumors
formed by inoculated SW480 colon cancer cells.
Fig. 3. (a) Effect of intraperitoneal injection of GSK-3β inhibitors on
proliferation of SW480 xenografts and (b) comparison of xenograft weights
in rodents treated with dimethyl sulfoxide (DMSO) and indicated doses
of the kinase inhibitors. (a) Tumor sizes were measured weekly and their
volumes calculated. Administered agents and their doses are indicated
on the right together with corresponding symbols. There was a dose-
dependent decrease in tumor volume both with SB-216763 and AR-
A014418 from week 5 and beyond (P < 0.05). (b) Mean weights ± SD of
the tumors removed at necropsy from the respective groups of mice with
indicated treatments. Statistically similar differences were found in tumor
weights between mice with the respective treatments. (a,b) There were no
statistically significant differences in tumor volume or weight between
mice treated with any dose of SB-216763 and AR-A014418, or between
mice treated with 2 mg/kg and 5 mg/kg of the inhibitors, respectively.
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representative paraffin sections, respectively (upper panels in
Fig. 4a,b). There were dose-dependent increases in TUNEL-
positive cell rates and decreases in PCNA-positive cell rates in
tumors treated either with SB-216763 or AR-A014418 (P < 0.05;
lower panels in Fig. 4a,b). Immunohistochemical examination
showed cytoplasmic expression of GSK-3β and cytoplasmic and
nuclear expression of β-catenin in tumor cells. No differences
were found in intensity of expression or subcellular localization
of these molecules between the tumor cell xenografts in mice
treated with DMSO and different doses of the small molecule
GSK-3β inhibitors (Fig. 5).
During treatment, all mice tolerated DMSO and increasing
doses of the GSK-3β inhibitors well. There were no adverse
events involving general appearance, body weight (Fig. 6) or
food intake (data not shown); as noted, at the beginning of the
treatment, one mouse in each of the groups treated with the
respective doses of the GSK-3β inhibitors died because of an acute,
lethal accident (i.e. intraperitoneal bleeding) due to intraperitoneal
injection. At necropsy, gross observation and histopathologic
examination showed no apparent pathological findings, neoplastic
lesions or metastatic tumors in the lungs, liver, pancreas, kidneys,
spleen or large bowel in all mice (not shown).
Discussion
The present study demonstrated a dose-dependent effect in vivo
of GSK-3β inhibitors against survival and proliferation of
human cancer cells xenografted into rodents. The effect was
associated with no apparent adverse events in general appearance,
body weight or food intake of the rodents. Unlike the report that
disruption of the murine GSK-3β gene results in embryonic
lethality caused by severe hepatocyte degeneration,(16,17) there
were no pathologic lesions in major organs, in particular, the
liver of rodents treated with the GSK-3β inhibitors. In a recent
series of studies the authors have demonstrated that the patho-
logic roles of GSK-3β are definite and common in various types
of gastrointestinal cancer by analysis of expression, phosphory-
lation, activity and function of the kinase in multiple cell lines
derived from colon, stomach, pancreas and liver cancers.(19,20)
Following these studies, the authors have monitored and found
in vivo effects of the GSK-3β inhibitors against xenografts of
a colon cancer cell line other than SW480 and a pancreas cancer
cell line in rodents by treatment with the kinase inhibitors
longer than 5 weeks; the treatment was associated with no
apparent adverse events (unpublished observations, 2007). The
results of the authors’ studies indicate that the GSK-3β inhibitors
would be a novel class of therapeutic agents for colon cancer in
the clinical setting. The dose-dependency of the effects of the
inhibitors with no adverse effects supports the hypothesis of a
specific inhibitory effect but not of a non-specific cytotoxic effect
of these compounds against cancer cell survival and proliferation
in vivo. Importantly, there was no detectable tumor other than
colon cancer cells xenograft in rodents treated with the GSK-3β
inhibitors, as discussed below.
Fig. 5. Expression and subcellular localization of GSK-3β and β-catenin
in xenografts of SW480 human colon cancer cells in mice treated with
dimethyl sulfoxide (DMSO) and 5 mg/kg of AR-A014418, respectively.
GSK-3β expression was found in the cytoplasm of cancer cells.
Cytoplasmic and nuclear accumulation of β-catenin was observed in
most cancer cells. No differences were found in intensity of expression
or subcellular localization of these molecules between the tumor cell
xenografts in mice treated with DMSO and AR-A014418. Nuclei were
counterstained with hematoxylin. The scale bar in each panel indicates
100 µm.
Fig. 6. Effect of intraperitoneal injection of GSK-3β inhibitors on body
weights of animals during the course of treatment. Body weights of
the mice were measured weekly for 3 weeks before inoculation of
SW480 colon cancer cells, as indicated with a minus number on
the week axis, and over the treatment. The results are displayed for
respective groups of mice with indicated doses (1 mg/kg, 2 mg/kg, and
5 mg/kg body weight) of GSK-3β inhibitors. All panels include the data
of body weights of mice treated with dimethyl sulfoxide (DMSO;
indicated by closed circles) as a control. No significant differences in
body weight were observed between the groups.
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The molecular mechanisms underlying the putative pathologic
roles of GSK-3β in cancer and the effect of GSK-3β inhibition
against cancer are of particular interest and under investigation.
Depending on the variety of its substrates for phosphorylation,
it is assumed that GSK-3β exerts disparate functions in cell sur-
vival and proliferation that depend on cell type and context in
both physiological cells,(4–6) and cancer cells.(15) Earlier studies
have indicated that GSK-3β is active against cancer, mimicking
a tumor suppressor, on the basis of its reported role as a repressor
in Wnt/β-catenin signaling,(27) expression of cyclin D1, c-Myc and
COX2,(28–30) and EMT by targeting snail.(31) Contrarily, since around
the time of the authors’ discovery of a Wnt signal-independent
novel pathologic role of GSK-3β in gastrointestinal cancer,(19,20) an
increasing number of reports have shown that active GSK-3β exerts
tumor-promoting functions. Such reports include the participation
of GSK-3β in increased resistance to apoptosis caused by TRAIL,(32)
p53,(21,33) and c-Myc,(34) NF-κB-mediated survival pathway,(22)
induction of cyclin D1 expression,(35) and regulation of cell adhesion
and migration.(36) The reported results of the conflicting roles of
GSK-3β in regulation of the same molecules, such as cyclin
D1,(17,35) and c-Myc,(29,34) are intriguing. All these reports concern
only the molecules and pathways known to be involved in can-
cer, and accordingly a systemic and comprehensive investigation
is necessary to clarify the unknown role of GSK-3β in the
pathology of cancer and its relevance to the fate of cancer cells.
Because of the nature of GSK-3β as a multitasking kinase,(4–6)
the systemic inhibition of GSK-3β seems to lead to some detri-
mental effects in the mouse body due to disturbing the normal
metabolism. However, no apparent detrimental effect was actu-
ally observed in rodents treated by intraperitoneal injection of
the GSK-3β inhibitors in the present study. Prior to the present
study the authors showed that, unlike the effects against various
types of cancer cells, there was no or little effect of inhibition of
activity or expression of GSK-3β on cell survival, proliferation
or apoptosis in HEK293 that was considered and used as a non-
neoplastic cell line.(19,20) This observation is supported by subse-
quent studies showing that neither GSK-3β inhibitors affected
cell survival or proliferation in cultured HMEC, embryonic lung
fibroblasts (WI38) or mouse embryonic fibroblasts (NIH-3T3).(22,37)
The authors’ previous study showing the presence of both GSK-3β
fractions phosphorylated at S9 and Y216 residues in HEK293
cells,(19) suggest that the kinase activity is seemingly regulated
by differential phosphorylation in these key residues depending
on stimuli in cells of non-neoplastic origin. This post-translational
modification of the kinase would underlie the putative mecha-
nism by which physiological cells in the major organs of rodents
are protected from detrimental effects by GSK-3β inhibition. In
contrast to these cells with a non-neoplastic nature, the authors found
overexpression and increased activity of GSK-3β and deregulation
in the balance between the levels of phosphorylation at its S9 and
Y216 residues in colon,(19,20) stomach, pancreas and liver cancer
cells (unpublished observation, 2007), indicating selective and
common effects of GSK-3β inhibition against cancer cells. Conse-
quently, different effects of GSK-3β inhibition in non-neoplastic
and neoplastic cells would depend on the differences in biolog-
ical properties and functions of the kinase in these cells.
The molecular pathways and mechanisms that include GSK-3β
as a crucial mediator have been implicated in the development
of diseases other than cancer, represented by NIDDM,(7–9) and
AD.(10,11) Apart from the molecular basis of the diseases, epide-
miological studies indicate an association in risk between cancer
and NIDDM,(38–41) or AD.(42) More recently, a line of studies
showing that Wnt/β-catenin signaling participates in bone
formation (reviewed in(43,44)) suggests that GSK-3β would be a
therapeutic target in osteoporotic bone disorders as a negative
regulator of the canonical Wnt signal pathway. Accordingly,
GSK-3β is expected to be a promising therapeutic target for
common adult-onset diseases (NIDDM, AD, bone disorders and
cancer) that share the characteristics of chronic and progressive
clinical course and resistance to standard treatments presently
available. In the present study, the authors treated tumor-burdened
mice with small-molecule GSK-3β inhibitors by means of repeated
intraperitoneal injections. However, a less invasive method,
namely oral administration, is required for long-term treatment
of chronic diseases such as these. With regard to the feasibility
of and compliance with the requirements of the drug delivery
system, recent efforts are being directed to the development of
an orally bioavailable GSK-3α/β dual inhibitor as a new drug
for osteoporosis.(45)
Clinical application of GSK-3β inhibitors to the treatment
of chronic diseases requires heightened awareness of safety con-
siderations. Given the primary roles of GSK-3β in regulating its
substrates, inhibition of GSK-3β results in up-regulation of various
proto-oncoproteins (e.g. β-catenin, cyclin D1, c-Myc, c-Jun),
leading to concern that long-term inhibition of GSK-3β may
increase the risk of carcinogenesis.(12) To date, however, the
investigators of a cohort study reported that long-term use of
lithium, the classical but non-specific GSK-3β inhibitor, increases
neither cancer morbidity nor mortality but rather is associated
with reduced overall mortality in patients with bipolar disor-
der.(46) Similarly, although safety issues involving mutagenicity
and carcinogenicity have not been available for lithium,(47) it has
been reported that lithium treatment did not significantly
increase the number of tumors in genetically predisposed APC
mutant mice.(48) This observation is supported by the present
study’s finding of no detectable tumor, other than the xenograft,
in the major organs, including the large bowel, after 5 weeks’
treatment with either SB-216763 or AR-A014418, even at the
maximum dose of 5 mg/kg. Furthermore, it has become evident
that inhibition of GSK-3β by itself might not be sufficient to
elevate the level of β-catenin in primary cells; and this might
only occur in cells in which one or more transforming events
such as APC protein truncation have already taken place.(49) In all,
the evidence at hand suggests that we can prevent cancer risk
caused by long-term GSK-3β inhibition if we generate a new
class of compounds which can appropriately control GSK-3β
expression and activity.
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